BNP Paribas Has $2.81 Million Stake in Boston Scientific Co. (NYSE:BSX)

BNP Paribas boosted its stake in Boston Scientific Co. (NYSE:BSX) by 120.3% in the third quarter, HoldingsChannel reports. The firm owned 33,505 shares of the medical equipment provider’s stock after buying an additional 18,299 shares during the period. BNP Paribas’ holdings in Boston Scientific were worth $2,807,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Triad Wealth Partners LLC bought a new position in Boston Scientific in the second quarter worth approximately $26,000. Values First Advisors Inc. bought a new position in shares of Boston Scientific in the 3rd quarter worth $28,000. E Fund Management Hong Kong Co. Ltd. acquired a new stake in Boston Scientific in the 3rd quarter valued at $30,000. Capital Performance Advisors LLP bought a new stake in Boston Scientific during the 3rd quarter valued at $30,000. Finally, Andra AP fonden acquired a new position in Boston Scientific during the second quarter worth $29,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, EVP Arthur C. Butcher sold 14,010 shares of Boston Scientific stock in a transaction on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the transaction, the executive vice president now directly owns 978 shares in the company, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Ludwig sold 4,877 shares of the stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the sale, the director now directly owns 39,398 shares in the company, valued at $3,610,038.74. This trade represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 328,157 shares of company stock worth $27,894,270. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Performance

Shares of BSX opened at $90.19 on Wednesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The firm has a market cap of $132.92 billion, a PE ratio of 74.54, a PEG ratio of 2.63 and a beta of 0.79. Boston Scientific Co. has a 1 year low of $53.93 and a 1 year high of $91.93. The stock’s fifty day moving average price is $86.26 and its two-hundred day moving average price is $80.44.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The business had revenue of $4.21 billion for the quarter, compared to analysts’ expectations of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The firm’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.50 EPS. On average, equities research analysts forecast that Boston Scientific Co. will post 2.46 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on BSX shares. BTIG Research boosted their target price on shares of Boston Scientific from $84.00 to $93.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Barclays increased their price objective on Boston Scientific from $78.00 to $86.00 and gave the stock an “overweight” rating in a research note on Thursday, August 22nd. Truist Financial lifted their target price on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, October 14th. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Finally, Canaccord Genuity Group lifted their price objective on shares of Boston Scientific from $88.00 to $98.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Four investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $93.39.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.